• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Confluence Pharmaceuticals receives $200K investment from IU fund

Bioengineer by Bioengineer
April 11, 2019
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Confluence Pharmaceuticals develops treatments for social and communication impairments related to autism spectrum disorder, fragile X syndrome

IMAGE

Credit: Teri Willey

BLOOMINGTON, Ind. — The Indiana University Philanthropic Venture Fund, which invests in IU-related ventures, has invested $200,000 in Confluence Pharmaceuticals LLC.

Confluence Pharmaceuticals is a Carmel, Indiana-based company that develops novel, clinically discovered, therapeutic treatments for core social and communication impairments related to fragile X syndrome and autism spectrum disorder.

Confluence Pharmaceuticals CEO Steve Johns said the company is targeting its lead asset, a product for the treatment of fragile X syndrome to improve important functionality including communication, social interaction and self-care.

“Today, no medication exists to treat these core impairments,” Johns said. “Early pilot studies have demonstrated the potential of our product to improve focus, communication, social withdrawal and attention deficit hyperactivity disorder.”

Confluence Pharmaceuticals will use the investment to accelerate clinical development and regulatory activities.

What they’re saying

Confluence Pharmaceuticals licenses intellectual property developed at Indiana University through the IU Innovation and Commercialization Office.

“We are delighted to have Indiana University broaden its relationship with us and become an investor as we enter the next stage of our development,” Johns said. “We look forward to continuing our collaborative relationship and utilizing the supportive resources IU brings to the development of this much-needed therapy.”

The IU Philanthropic Venture Fund was launched in February 2018. Teri Willey is the fund manager and executive director of the IU Research and Technology Corp.

“We, too, are delighted to be supporting the team at Confluence in their efforts to bring this critical therapy to patients, and to have Confluence as our 10th investment since launching the fund a few months ago,” Willey said.

About Indiana University Research and Technology Corp.

IURTC catalyzes entrepreneurial activities at Indiana University and provides support for IU innovation-based startup companies. It advises and connects IU startups to capital and commercialization partners, industry mentors, and leadership talent. It also develops appropriate programming and startup space to accelerate company growth.

About Indiana University Philanthropic Venture Fund

The IU Philanthropic Venture Fund is an Indiana University-affiliated venture fund launched in 2018 through the vision and generosity of IU alumni and friends supporting IU discoveries best developed through a new venture. The fund is managed by IURTC staff who work with the IU Innovation and Commercialization Office, alumni, faculty, and staff, as well as the venture and economic development communities, to identify and develop IU-related opportunities for investment.

###

Media Contact
Steve Martin
[email protected]

Original Source

https://news.iu.edu/stories/2019/04/iu/11-confluence-pharmaceuticals-autism-fragile-x-investment-philanthropic-venture-fund.html?&ntm_campaign=iu_news&ntm_medium=web&ntm_source=news.iu.edu/topic/business-and-innovation/index.html&ntm_term=feature&ntm

Tags: Grants/FundingMedicine/HealthPharmaceutical Sciences
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Ultrafast Polaron Formation in NaTaO3 Reveals Instant Stabilization of Positive Charges in Key Solar Fuel Catalyst

September 30, 2025
blank

New Supramolecular Elastomer with Boron-Based Dynamic Bonds Delivers Superior Mechanical Strength and Chemical Recovery

September 30, 2025

New Study Uncovers Why Modern Proteins Were Selected by Nature

September 29, 2025

Global Call to Advance Robust and Reproducible Polyphenol Research to Launch Next October in Malta at Polyphenols Applications World Congress and Iprona

September 29, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    87 shares
    Share 35 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    59 shares
    Share 24 Tweet 15
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Assessing Falls Risk Awareness in Seniors and Caregivers

Tunable Microstructures in Bionic Bone Scaffold Design

Hybrid Genetic Algorithm Optimizes Neural Network Image Restoration

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.